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Thirty leading scientists in the field of
Parkinson's disease research attended a con-
ference, "The Role of the Environment in
Parkinson's Disease," 17-19 September
1995, sponsored and hosted by the
National Institute ofEnvironmental Health
Sciences. Parkinson's disease investigators
working in various basic and clinical disci-
plines presented and evaluated current sci-
entific findings concerning the etiology of
the disease and charted the most fruitful
courses for future research. The role of the
environment was highlighted, but consider-
able attention was given to pathological
neurochemistry and genetic issues in the
etiopathogenesis ofParkinson's disease.
The conference was opened by Annette
Kirshner, program administrator at NIEHS
and chair of the conference, who framed
the context ofthe discussions to take place.
Terri Damstra, acting deputy director of
NIEHS, welcomed attendees to the insti-
tute and reaffirmed the importance of the
work to NIEHS. She emphasized that in
Parkinson's disease the potential roles of
environmental exposure to one or more
agents, genetic susceptibility to such expo-
sures, and the factor of time or aging are
likely to play roles in the etiology of the
neurodegenerative process.
Formal presentations were divided into
three sessions: environmental and genetic
risk factors (Doyle Graham, chair), neuro-
toxins and mechanisms of neuronal injury
(ay M. Gorell, chair), and biological mark-
ers of Parkinson's disease (Donato
DiMonte, chair). Summaries of each of
these sessions follow.
Environmental and Genetic Risk
Factors
The relative roles ofenvironmental, endoge-
nous neurochemical and genetic factors in
the etiology of Parkinson's disease is cur-
rently unclear. For example, the prevalence
ofParkinson's disease in a community could
be due to a differential distribution of a
hypothetical environmental toxicant or be
more frequent where a heritable defect is
common. Twin studies in the 1980s seemed
to discount a significant genetic role in
Parkinson's disease when the degree ofcon-
cordance between monozygotic and dizygot-
ic pairs was found to be similar. An environ-
mental cause of the disease was favored
when it was shown that 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) could
enter the brain and be metabolized to 1-
methyl-4-phenylpyridinium ion (MPP+),
which could specifically destroy nigral neu-
rons to produce a human condition that
closely mimicked Parkinson's disease.
Moreover, the fact that the amyotrophic
lateral sderosis/Parkinson's disease/demen-
tia complex could develop in Guamanians
decades after their migration from the
island strengthened the idea that a long
latent period after exposure to an environ-
mental toxicant could be present before a
degenerative disorder was fullymanifest.
The potential role of genetics in
Parkinson's disease was raised again when a
number of families with parkinsonism in
several generations was reported. Few
affected individuals have been autopsied
thus far, but typical Lewy body histo-
pathology has been found. Some investiga-
tors believe that many more familial
Parkinson's disease cases will be found,
but, clearly, a biomarker of genetic risk
would be optimal for case identification.
Allelic association studies and DNA link-
age analysis have not tied the occurrence of
Parkinson's disease to various candidate
genes so far, though a systematic search of
the human genome is underway.
As work on genetics proceeds, much
productive research continues to identify
endogenous neurochemical abnormalities,
to study the mechanisms ofaction ofneuro-
toxins, and to characterize environmental
risk factors that may either initiate or per-
petuate Parkinson's disease. In the epidemi-
ologic literature, Parkinson's disease has
been consistently shown to increase with
either advancing age or the passage oftime
and to be slightly more prevalent in males.
Moreover, nearly all studies report an
inverse (i.e., protective) association of
Parkinson's disease with smoking, though
the mechanism bywhich this influences risk
is unclear. Some studies have suggested a
decreased risk ofParkinson's disease with a
higher intake of antioxidant vitamins, and
many others have found an increased risk of
Parkinson's disease among those who have
lived in rural environments, farmed, or been
exposed to pesticides or towellwater.
Two population-based case-control
studies have been conducted. Semchuk
and colleagues, at the Universities of
Calgary and Saskatchewan, found that a
family history of Parkinson's disease was
the strongest predictor of Parkinson's dis-
ease risk, followed by a history of head
injury severe enough to require medical
attention, and then by a history ofoccupa-
tional exposure to herbicides. Gorell and
colleagues, at Henry Ford Hospital in
Detroit, Michigan found an increased risk
of Parkinson's disease with more than 10
years of occupational exposure to copper,
manganese, or lead, but no increased risk
with iron, zinc, or mercury exposure. Gorell
et al. also found an increased risk of
Parkinson's disease with occupational expo-
sure to either herbicides or insecticides.
There is active investigation ofpotential
risk of Parkinson's disease in the systemic
metabolism ofxenobiotics, operating either
via cytochrome P450 enzymes (e.g.,
CYP2D6 in the detoxication ofMPTP and
isoquinolines) or through impaired sulfation
and sulfoxidation. Finally, there is an ongo-
ing, large study of identical twins, examin-
ing their concordance for Parkinson's dis-
ease, which could-help define the relative
roles ofgenetic and nongenetic factors.
Ultimately, there may be a varying mix-
ture offactors that produce Parkinson's dis-
ease in different human populations. For
example, in families showing an autosomal
dominant pattern of Parkinson's disease
transmission, genetic factors may dominate.
Among other populations (currently
believed to account for the majorityofcases)
a variety ofenvironmentally acquired neuro-
toxic exposure(s) may interact under the
oxidatively stressed conditions in the
Parkinson's disease substantia nigra (SN) to
produce the disease. More than one agent
(e.g., xenobiotics, metals) may produce
Parkinson's disease in sequential stages.
Finally, various nongenetic and genetic
mechanisms may be linked ifthe genome is
damaged by environmental or endogenous
toxins. However, any model proposed to
explain the occurrence ofParkinson's disease
must account for the selective vulnerability
of nigral neurons, the susceptibility of par-
ticularindividuals, and disease progression.
Neurotoxins andMechanisms of
Neuronal Injury
The chemical pathology of neuromelanin
and oxidative stress in Parkinson's disease
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may be pivotal in nigral neuronal death.
Neuromelanin, made from orthoquinones
derived from catecholamine metabolism,
forms during the gradual depopulation of
pigmented catecholaminergic neurons in
the central nervous system in Parkinson's
disease. The chemical milieu surrounding
neuromelanin is characterized by transition
metal-catalyzed redox cycling between
semiquinone and catecholamine com-
pounds, as well as by the formation of
hydrogen peroxide from the catabolism of
catecholamines by either the action of
monoamine oxidase (MAO) or by their
autoxidation. Cellular factors that increase
SN oxidative reactions, such as potential
activation ofxenobiotics by MAO (as with
MPTP), interference with mitochondrial
oxidative phosphorylation (e.g., by inhibi-
tion ofcomplex I), or action by excitotox-
ins, can exacerbate local oxidative stress.
There is an apparently Parkinson's dis-
ease-specific 35-40% decrease in SN mito-
chondrial complex I function, the same
defect seen with MPP+ action. This defi-
ciency could generate superoxide and other
free radicals that may contribute to neu-
ronal damage in the SN. However, it is
unclear whether the SN complex I deficien-
cy in Parkinson's disease is due to genetic
damage, exogenous or endogenous factors,
or both. A possible genetic defect may be
due to alterations in nuclear and/or mito-
chondrial DNA, as several complex I sub-
units are encoded bymitochondrial DNA.
Pharmacological study of model sys-
tems such as P19 neuroglial cultures can
shed further light on neurochemical
changes in oxidatively stressed brain. For
example, the cytotoxicity of lipophilic
dopamine congeners in this system is
enhanced by manganese coincubation and
is associated with cross linking ofneurofila-
ment protein into high molecular weight
aggregates. Moreover, redox-cycling cate-
chols induce lipid peroxidation that gener-
ates E-4-hydroxy-2-nonenal, a protein
crosslinking agent. These results suggest
that lipid peroxidation, and perhaps Lewy
body formation with subsequent neurode-
generation, may be related to catechol oxi-
dation.
Iron levels are increased approximately
35% in the Parkinson's disease SN zona
compacta, and laser microprobe and X-ray
microanalysis studies show increased iron
(and aluminum) in SN neuromelanin in
such patients. Moreover, iron infusion into
SN in animals can cause both acute and
progressive neuronal loss. The importance
of these findings may lie in the fact that
iron, if liberated from neuromelanin (or
ferritin) stores, can greatly potentiate the
formation ofhighly cytotoxic hydroxyl rad-
icals from hydrogen peroxide, which is pro-
duced from dopamine metabolism. This
process may be more likely in the
Parkinson's disease brain, in which a defi-
ciency of reduced glutathione (GSH), the
major defense against hydroxyl radical for-
mation, has been found.
In a monkey model ofmanganism pro-
ducea by intravenous infusion of MnCI2,
the metal accumulated in putamen, with a
subsequent massive periventricular accu-
mulation of iron and an increase in alu-
minum in globus pallidus. These findings
raise the possibility that environmental
exposure to manganese may also reflect
exposure to iron and aluminum. Because
the liver is the major organ involved in the
clearance of manganese, liver failure could
predispose an individual to manganese-
induced neurotoxicity. Finally, though alu-
minum does not promote lipid peroxida-
tion, it greatly potentiates the ability of
iron to do so, raising the possibility that all
three metals may participate in the patho-
genesis ofParkinson's disease.
Several classes ofneurotoxins have been
studied as potential nigral toxins, with
varying results. For example, some f-car-
boline compounds are structurally similar
to MPP+ and have been shown to inhibit
mitochondrial complex I. Though sub-
stances studied so far do not show
dopaminergic cytotoxic specificity in rat
primary mesencephalic cultures, 2,9-di-N-
methyl P-carbolinium derivatives are
detectable in the cerebrospinal fluid of
some Parkinson's disease patients, and such
compounds are eight-fold more concentrat-
ed in Parkinson's disease SN than in cere-
bral cortex. The organochlorine pesticide
dieldrin was present in 6 of20 Parkinson's
disease brains in one study, though it was
not more concentrated in Parkinson's dis-
ease samples, suggesting that it was not suf-
ficient to cause Parkinson's disease.
Four models were considered in the
identification of agents with potential SN
toxicity: 1) utilization of the dopamine
uptake system in nigrostriatal neurons to
confer specificity (e.g., MPP+); 2) interac-
tion of toxins with dopamine (e.g.,
methamphetamine-induced striatal termi-
nal damage); 3) utilization of iron in free
radical generation and/or in the bioactiva-
tion ofan environmental toxin (e.g., MPP+
generation by iron-activated, MAO-inde-
pendent means); and 4) potentiating effects
of two agents at one or more sites (e.g.,
diethyldithiocarbamate plus L-dopa may
act by inhibition of superoxide dismutase,
increased bioactivation by MAO, decreased
dopamine re-uptake, decreased mitochon-
drial oxidative function, and by gluta-
matergic excitotoxicity).
Biological Markers
Brainstem Lewy body formation is a neu-
ropathological hallmark in the diagnosis of
Parkinson's disease postmortem. However,
little is known about its role in the patho-
genesis ofParkinson's disease, nor is much
known about the role of neuronal inclu-
sions in MPTP-parkinsonism. The reasons
for differences in the inclusions in these
disorders is needed to clarify the pathogen-
esis of both Parkinson's disease and
MPTP-parkinsonism.
Thus far, it has not been possible to
find a specific biomarker of Parkinson's
disease in accessible tissues of living
patients. For example, there has been an
extensive search for a mitochondrial com-
plex I defect in peripheral tissues. However,
the existence such a deficiency in skeletal
muscle is in doubt. Moreover, the consis-
tent decrease in complex I activity in
Parkinson's disease platelets shows overlap
with control values, and the extent of the
deficiency is variable.
No significant associations have been
found between superoxide dismutase-1
(SOD-1), Huntington (IT-15), ApoE4 and
ApoE3, CYP2D6 alleles, or MAO-A hap-
lotypes and Parkinson's disease. Analysis
has failed to show genetic linkage in three
Parkinson's disease families with glu-
tathione peroxidase, tyrosine hydroxylase,
amyloid precursor protein, SOD-1,
CYP2D6, or chromosomal regions express-
ing choline acetyltransferase or brain-
derived neurotrophic factor. Further stud-
ies are in progress to define a role for a
mutant allele of CYP2D6 and to test the
hypothesis that alterations in detoxification
enzymes may be markers ofrisk factors for
Parkinson's disease.
The value ofcerebrospinal fluid data as
a marker of the dopaminergic system in
Parkinson's disease has been limited. A
decrease in cerebrospinal fluid homovanillic
acid (HVA) has been shown in Parkinson's
disease in many, but not all, studies, and
there is no correlation between the HVA
level and either the duration or severity of
the disease. There has been no follow-up of
an earlier report suggesting that the 5-S-cys-
teinyl forms ofdopamine, DOPAC and L-
dopa, in cerebrospinal fluid may be indices
ofoxidative stress in basal ganglia.
Imaging studies offer promise in provid-
ing markers of Parkinson's disease. For
example, positron emission tomography
(PET) studies have shown a linear correla-
tion between the extent of reduced 6-fluo-
rodopa uptake in striatum and the numbers
of SN neurons in subsequent autopsies in
some Parkinson's disease patients. Higher
resolution PET scanners can differentiate
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caudate and putamen, and Parkinson's dis-
ease patients can be completely separated
from control subjects. The two populations
can be mostly resolved by imaging striatal
binding of the dopamine antagonist raclo-
pride. The single-photon emission tomog-
raphy radioligand, [I23I]P-carbomethoxy-3-
P(4-iodophenyl)-tropane, a cocaine ana-
logue that binds to the dopamine trans-
porter in striatum, has been used to show a
direct relationship between diminished
uptake and motor disability in Parkinson's
disease patients. Finally, a new MRI
method has been developed to assess iron
accumulation at 3 Tesla in SN. The
method relies on the calculation of 1/T2'
(R2'), the relaxation rate due to local para-
magnetic material. R2' in the dark area of
the SN on T2 or T2*-weighted images is
significantly higher in Parkinson's disease
patients, and does not overlap with control
values, reflecting the higher iron content in
Parkinson's disease SN postmortem. A
direct correlation has been shown between
the right/left asymmetry of SN R2' versus
the left/right asymmetry ofsimple reaction
time in Parkinson's disease subjects, sug-
gesting that SN iron accumulation is related
to disease severity.
Conclusions
Areas offocus for future research were identi-
fied, which should be pursued by several
NIH institutes. Epidemiological studies need
to 1) identify exposures to particular toxins
that can specifically damage SN or other
basal ganglionic structures, 2) clarify the age-
specific rates ofdisease to understand trends
over time, 3) more specifically define risk
factors being assessed, 4) examine whether a
family history of other neurodegenerative
diseases increases the risk for Parkinson's dis-
ease, 5) study Parkinson's disease subgroups
(e.g., young, old, familial, and nonfamilial
cases) to determine differential risk for
acquiring the disease, and 6) bank specimens
ofblood and other tissues to link environ-
mental exposures to markers of Parkinson's
disease; i.e., of the disease itself, of mecha-
nisms ofbiochemical damage, and ofpoten-
tial genetic risk. Finding biomarkers for
Parkinson's disease would enhance the relia-
bility ofclinical diagnosis, helping to ensure
the homogeneity ofcases selected for clinical
and epidemiologic studies; permit preclinical
diagnosis, enabling full ascertainment of
familial cases, identification of those at risk
for selected environmental toxicants, and
allowselection ofindividuals for trials ofpos-
sibly neuroprotective drugs; potentially per-
mit the screening oflarge populations; and
possibly provide clues about the etiopatho-
genesis ofthe disease.
Understanding the mechanism(s)
underlying brainstem Lewy body formation
and its role in the neurochemical pathology
of Parkinson's disease could elucidate the
etiopathogenesis of the condition. Identi-
fying early or initiating neurochemical
events is critical, including factors confer-
ring selective vulnerability or protection to
nigral neurons (e.g., chemical characteristics
oftoxins; the role ofglial cells in the bioac-
tivation oftoxins or in providing neuropro-
tection; neurotrophic factors). The role of
bioaccumulation of toxicants (e.g., metals,
glutamate, pesticides, infectious agents, oth-
ers), with slow release over time, should be
investigated. The development ofmodels of
chronic in vivo neurotoxicity that more
closely resemble the progressive nature of
Parkinson's disease should be a priority.
Continued search for one or more genes
in Parkinson's disease with linkage to brain-
stem Lewy body pathology is an important
area of investigation. More autopsies are
needed in large kindreds to establish the
pathological basis for their clinical condi-
tion. Results ofthe ongoing study ofa large
number of identical twins with one
Parkinson's disease twin could clarify a
potential genetic role in Parkinson's disease.
The potential interaction between the
environment, pathological neurochemistry,
anatomy, and genetic factors was seen as
the most fruitful overall research direction
to unravel the etiology and pathogenesis of
Parkinson's disease. Sharing insights in the
basic and clinical neurosciences is the best
vehicle for maximally using diverse scientif-
ic talent. Interdisciplinary research should
be encouraged by NIH institutes.
Co-sponsors oftheWorkshop
on the Role ofthe Environment in
Parkinson's Disease
NIEHS Division ofExtramural Research
and Training





















1996International Course on the
Safety Assessment of Pharmaceuticals
The rican Health Foundation's 4th International Course on the Safety Assessment of Pharmaceuticals, Part 1,
ft st cts, is designed mainly for scientists of the pharmaceutical industry in charge of nonclinical or clini-
iis :talso for those responsible for the registration of new drugs. Participants will receive the scientific
inf n necessary for a sound comprehension of the results of nonclinical safety studies. Toxicologists and toxi-
col thologists will also benefit from this course by updating their knowledge. The course will be held on
October 20-25, 1996, at the Crowne Plaza in the heart of White Plains, New York, just 35 minutes north of New
York City. For a brochure and registration information, please contact Ms. Nancy Rivera at the American Health
Foundation, 1 Dana Road, Valhalla, NY 10595-1599; telephone (914) 789-7144, FAX: (914) 592-6317.
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